Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avalglucosidase alfa in treatment-naive infants with infantile-onset Pompe disease
NL-OMON52076Phase 3Not yet recruiting
- Sponsor
- Sanofi
- Start
- May 2021
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of avalglucosidase alfa in Pompe disease, sponsored by Sanofi. Primary endpoint: Survival and invasive ventilator-free survival at Week 52. Planned start May 2021; status: not yet recruiting.
02
Drugs
avalglucosidase alfa
03
Conditions
Pompe disease
Beyond the preview
Go deeper on NL-OMON52076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52076.